Clinical Trials at Essentia Health Saint Joseph's Medical Center
As of August 2026, 52 paid clinical trials are recruiting at Essentia Health Saint Joseph's Medical Center, located at Essentia Health-St. Joseph's Medical Ctr (Brainerd), 523 N 3rd St, Brainerd, MN 56401, phone (218) 829-2861 in Brainerd, Minnesota. Active studies at this site cover conditions such as Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 and Breast Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
52 clinical trials at Essentia Health Saint Joseph's Medical Center
·Clear filters·Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Family Communications After Genetic Testing
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
E-Mindfulness Approaches for Living After Breast Cancer
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Common conditions studied in Brainerd
- Anatomic Stage II Breast Cancer AJCC v8 (5 active studies)
- Anatomic Stage IIIA Breast Cancer AJCC v8 (3 active studies)
- Breast Cancer (3 active studies)
- Lung Non-Small Cell Carcinoma (3 active studies)
- Melanoma (3 active studies)
- Advanced Esophageal Adenocarcinoma (2 active studies)
Leading research sponsors in Brainerd
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- NRG Oncology
- SWOG Cancer Research Network
- Wake Forest University Health Sciences
Frequently asked questions
How many paid clinical trials are currently recruiting in Brainerd?
There are approximately 56 recruiting clinical trials in Brainerd, Minnesota listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Brainerd pay participants?
Most recruiting trials in Brainerd compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Brainerd?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Brainerd?
The most common conditions under active study in Brainerd include Anatomic Stage II Breast Cancer AJCC v8 (5), Anatomic Stage IIIA Breast Cancer AJCC v8 (3), Breast Cancer (3), Lung Non-Small Cell Carcinoma (3), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Brainerd?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Brainerd on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Brainerd?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Brainerd?
Recruiting research sites in Brainerd include Essentia Health Saint Joseph's Medical Center, Essentia Health St. Joseph's Medical Center, Essentia Health-St. Joseph's Medical Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Brainerd right now?
The largest active categories in Brainerd are Cancer & tumors (49), Mental health & behavior (2). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Essentia Health Saint Joseph's Medical Center?
Essentia Health Saint Joseph's Medical Center is located at Essentia Health-St. Joseph's Medical Ctr (Brainerd), 523 N 3rd St, Brainerd, MN 56401. Use the Google Maps link in the intro above to get directions.
How do I contact Essentia Health Saint Joseph's Medical Center?
You can reach Essentia Health Saint Joseph's Medical Center by phone at (218) 829-2861. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.